Current practice of radioiodine treatment in the management of differentiated thyroid cancer in Germany

Hoelzer, Simon; Steiner, Dagmar; Bauer, Richard; Reiners, Christoph; Farahati, Jamshid; Hundahl, Scott A.; Dudeck, Joachim
October 2000
European Journal of Nuclear Medicine;2000, Vol. 27 Issue 10, p1465
Academic Journal
Abstract. This prospective, observational study of a cohort of thyroid cancer patients in Germany focusses on the "real-world" practice in the management of thyroid cancer patients. This report includes data from 2376 patients with primary differentiated thyroid carcinoma first diagnosed in the year 1996. The study reveals considerable differences in actual practice concerning surgery and radioiodine treatment. The results indicate that consensus is lacking with respect to the multimodality treatment approach for differentiated thyroid carcinoma. Our analysis represents the most current and comprehensive national assessment of presenting patient characteristics, diagnostic tests, treatment and complications for thyroid cancer.


Related Articles

  • Glitazone pretreatment boosted 1-131 uptake. Foster, Melissa // Endocrine Today;Dec2011, Vol. 9 Issue 12, p24 

    The article reports on a study which found that a short course of treatment with glitazone before radioiodine ablation enhances the uptake of radioactive iodine by cancer cells which could improve the treatment of metastatic differentiated thyroid cancer.

  • Reply. Sabri, O. // European Journal of Nuclear Medicine;2001, Vol. 28 Issue 3, p394 

    Replies to a comment made on an article about the treatment of differentiated nonmedullary thyroid carcinoma. Effect of thyroid uptake of a second application of radioiodine; Results of a reduction in thyroid uptake; Difficulty in quantifying how much of the administered radioiodine is absorbed...

  • Evidence supports optional use of RAI for papillary thyroid cancer. Calabro, Anthony; Costa, Samantha; Foster, Melissa // Endocrine Today;Oct2012, Vol. 10 Issue 10, p16 

    The article reports that Iain J. Nixon, MBCHB, clinical fellow in the head and neck surgery department of Memorial Sloan-Kettering Cancer Center, has argued for the optional use of radioactive iodine for the management of papillary thyroid cancer.

  • Historical Note: TSH Suppression for Thyroid Cancer. Hurley, James R. // Thyroid;Nov2011, Vol. 21 Issue 11, p1175 

    The article discusses the suppression of thyroid-stimulating hormone (TSH) for thyroid cancer treatment. The author notes the rapid advances in thyroid disease diagnosis and treatment due to radioiodine availability in the 1940s. He presents some findings on TSH suppression as well as the...

  • Three-dimensional radiobiological dosimetry (3D-RD) with I PET for I therapy of thyroid cancer. Sgouros, George; Hobbs, Robert F.; Atkins, Francis B.; Nostrand, Douglas Van; Ladenson, Paul W.; Wahl, Richard L. // European Journal of Nuclear Medicine & Molecular Imaging;May2011 Supplement 1, Vol. 38, p41 

    Radioiodine therapy of thyroid cancer was the first and remains among the most successful radiopharmaceutical (RPT) treatments of cancer although its clinical use is based on imprecise dosimetry. The positron emitting radioiodine, I, in combination with positron emission tomography (PET)/CT has...

  • Radioiodine Treatment of Differentiated Thyroid Carcinoma: The Experience at Seoul National University Hospital. Lee, Ho Young; Chung, June-Key; Lee, Jong Jin; Oh, So Won; Kang, Keon Wook; Park, Do Joon; Cho, Bo Youn; Lee, Myung Chul // Current Medical Imaging Reviews;2010, Vol. 6 Issue 1, p2 

    Radioactive iodine therapy has played an important role in the management of differentiated thyroid cancer (DTC) since specific accumulation of iodide in the thyroid gland was initially reported. The incidence of thyroid cancer is increasing in many countries including Korea. Conventional RIT...

  • Efficacy and Safety of Radioiodine in the Treatment of Disseminated Differentiated Thyroid Cancer in Children. Handkiewicz-Junak, Daria; Kropinska, Aleksandra // European Paediatrics;2010, Vol. 4, p19 

    Paediatric thyroid cancer is a rare disease, with well under 15% of all differentiated thyroid cancers (DTC) being diagnosed in childhood. Although DTC in paediatric patients frequently presents with metastases (60-80% nodal and 10-20% distant), the presence of metastases does not seem to...

  • The role of radioactive iodine in salivary gland dysfunction. Newkirk, Kenneth A.; Ringel, Matthew D.; Wartofsky, Leonard; Burman, Kenneth D. // ENT: Ear, Nose & Throat Journal;Jun2000, Vol. 79 Issue 6, p460 

    The use of radioactive iodine has become an important adjunct to the treatment of thyroid cancer. Many normal tissues--including salivary glands, gastrointestinal mucosa, gonads, and lactating breast tissue--have the ability to concentrate radioactive iodine under normal circumstances. Although...

  • The Effect of Ginkgo biloba Extract on Genotoxic Damage in Patients with Differentiated Thyroid Carcinoma Receiving Thyroid Remnant Ablation with Iodine-131. Dardano, Angela; Ballardin, Michela; Caraccio, Nadia; Boni, Giuseppe; Traino, Claudio; Mariani, Giuliano; Ferdeghini, Marco; Barale, Roberto; Monzani, Fabio // Thyroid; 

    Background: Radioiodine (131I) therapy is usually performed in patients with differentiated thyroid cancer (DTC). Although 131I is generally considered safe, genotoxic damage has been demonstrated both in vivo and in vitro. The aim of the current study was to evaluate the effect of Ginkgo biloba...


Read the Article


Sorry, but this item is not currently available from your library.

Try another library?
Sign out of this library

Other Topics